Pyxis Oncology Q1 net loss $21.2M ($0.35); cash $106.9M; MICVO data on track for H2 2025

Pyxis Oncology, Inc.

2025-Q1 EPS reported -$0.35

Net loss $21.2M ($0.35/share) vs $3.3M ($0.06) in Q1 2024; prior year included $16.1M Novartis settlement revenue.
Cash and investments $106.9M as of March 31, 2025; expected runway into second half of 2026.
R&D expenses rose to $17.0M from $13.0M, driven by increased clinical and manufacturing costs for MICVO.
On track to report Phase 1 monotherapy data for MICVO in HNSCC in H2 2025 and combination with pembrolizumab in H2 2025.
Preclinical data confirm three-pronged mechanism of MICVO (direct killing, bystander effect, immunogenic cell death).

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.